Plus Therapeutics reports FY2023 net loss $13.3M; cash $8.6M; ReSPECT-LM advances to Cohort 5

PLUS THERAPEUTICS, INC.

Net loss $(13.3)M ($4.24 per share) vs $(20.3)M ($11.58 per share) in 2022; operating loss improved to $13.3M from $19.7M.
Cash at Dec 31, 2023 was $8.6M, down from $18.1M; runway forecast into 2H 2025.
Enrolled 5th of 7 dosing cohorts in ReSPECT-LM Phase 1 trial for leptomeningeal metastases; orphan drug designation granted for breast cancer LM.
Received $3.3M advance from CPRIT grant ($17.6M total); total grant revenue recognized $4.9M in 2023.
Plans FDA meetings in 2024 to align on pivotal trial design for LM and GBM; registrational trial target 1H 2025.

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

PLUS THERAPEUTICS, INC. reported the fourth quarter and year ended December 31, 2023 results: net income $(13.3) million, or $(4.24) per share, EPS $(4.24) per share.

Period: the fourth quarter and year ended December 31, 2023
Net income: $(13.3) million, or $(4.24) per share
EPS: $(4.24) per share
Result: reported results

Exact text from the filing

Plus Therapeutics, Inc. (the “Company”) reported financial results for the fourth quarter and year ended December 31, 2023

View on SEC.gov

39 earnings releases filed in the last 30 days. Browse all earnings releases →

PLUS THERAPEUTICS, INC. filing history →

Source: SEC EDGAR

accession 0000950170-24-025866

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.